

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. Which of the following drug types best describes the novel agent upifitamab rilsodotin, under investigation for platinum-resistant ovarian cancer (OC)?**
 - a. PARP inhibitor
 - b. Checkpoint inhibitor
 - c. Antibody drug conjugate**
 - d. Tyrosine kinase inhibitor
- 2. What was the maximum duration of treatment with olaparib in the Phase III SOLO-1 trial and niraparib in the Phase III PRIMA trial of PARP inhibitor maintenance therapy after debulking surgery and first-line platinum-based chemotherapy for patients with advanced OC?**
 - a. Two years for both
 - b. Three years for both
 - c. Two years for olaparib, 3 years for niraparib**
 - d. Two years for niraparib, 3 years for olaparib
- 3. Which of following side effects are associated with PARP inhibitors in the treatment of OC?**
 - a. Hematologic toxicities only
 - b. Gastrointestinal toxicities only
 - c. Both hematologic and gastrointestinal toxicities**
- 4. Which of the following strategies under investigation for OC involves disrupting tumor cell proliferation with alternating electromagnetic fields?**
 - a. Diffuse optical tomography
 - b. Tumor treating fields**
 - c. Alternative electromagnetic fields
 - d. Electrical impedance